Parexel Informatics and Imaging Business Relaunches as Calyx

January 11, 2021
BioPharm International Editors

A strategic separation is designed to enhance the value and growth of Paraxel’s contract research services and Calyx’s imaging businesses.

Contract research organization (CRO) Parexel announced on Jan. 11, 2021 that the company completed a strategic separation of its Informatics and Medical Imaging business, which has been established as a new company named Calyx.

Gavin Nichols will serve as chief executive officer of Calyx; the company will employ approximately 2300 employees at headquarters in Nottingham, United Kingdom, and Durham, NC. Calyx will remain privately held by the ownership group that has owned Parexel since 2017.

Parexel will continue to use Calyx’s medical imaging, clinical trial management systems, electronic data capture, interactive response technology, and regulatory information management solutions as part of the company’s clinical development offerings, Paraxel reported.

“Today our industry needs to move at a 21st-century pace, and Calyx, as an independent company, is focused on enabling global biopharmaceutical customers and [CROs] to leverage innovative technology solutions and services in the pursuit of cures,” said Gavin Nichols, in a Calyx press statement. “While the name is new, Calyx has a long history of solving complex problems to accelerate new product development—from selecting the right biomarker in early-stage imaging to the electronic management of entire global development programs. We’re excited about this next stage of our journey.”

"Today's announcement marks a significant milestone as we further position Parexel to expect accelerated growth and performance as a top-tier CRO," said Jamie Macdonald, chief executive officer of Parexel, in a press statement. "We believe the separation will provide Calyx the opportunity to prioritize investments in technology development, customer delivery, and customer relationships while enabling the Parexel corporate business to strengthen its focus on the delivery of innovative clinical development solutions that reinforce our patients-first focus and advance world health.”

Sources: Paraxel and Calyx